Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


25.03.2024

1 Am J Clin Pathol
2 Am J Hematol
2 Ann Hematol
1 Biochem Pharmacol
2 Blood
1 Br J Cancer
2 Br J Haematol
1 Cancer
5 Eur J Haematol
1 Exp Hematol
3 Int J Hematol
1 J Clin Oncol
2 Leuk Lymphoma
2 Leuk Res
1 Oncogene
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Pathol

  1. DEMINA I, Mikhailova E, Zerkalenkova E, Semchenkova A, et al
    Laboratory characterization of the pediatric B/T subtype of mixed-phenotype acute leukemia: Report of a case series.
    Am J Clin Pathol. 2024 Mar 21:aqae020. doi: 10.1093.
    PubMed         Abstract available


    Am J Hematol

  2. LITZOW MR
    Building a better blinatumomab.
    Am J Hematol. 2024;99:512-514.
    PubMed        

  3. HU S, Jabbour EJ, Hu CY, Tang G, et al
    Recurrent lymphoid and myeloid relapses due to treatment cessations reveal natural history of Ph-positive B-ALL and pose a diagnostic challenge.
    Am J Hematol. 2024;99:721-726.
    PubMed        


    Ann Hematol

  4. KUROSAWA S, Yokota T, Takada Y, Okubo S, et al
    Effective treatment of pleural effusion in chronic lymphocytic leukemia with acalabrutinib: a case report.
    Ann Hematol. 2024 Mar 21. doi: 10.1007/s00277-024-05721.
    PubMed        

  5. HUANG XT, Wang CJ, Gao C, Xue TL, et al
    Relationship between subtype-specific minimal residual disease level and long-term prognosis in children with acute lymphoblastic leukemia.
    Ann Hematol. 2024 Mar 18. doi: 10.1007/s00277-024-05687.
    PubMed         Abstract available


    Biochem Pharmacol

  6. DI GIORGIO C, Morretta E, Lupia A, Bellini R, et al
    Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor (LIF) receptor in oncogenesis.
    Biochem Pharmacol. 2024;223:116134.
    PubMed         Abstract available


    Blood

  7. KLEIN K, Kollmann S, Hiesinger A, List J, et al
    A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia.
    Blood. 2024 Mar 18:blood.2023022655. doi: 10.1182/blood.2023022655.
    PubMed         Abstract available

  8. BAUMGARTNER F, Baer C, Bamopoulos S, Ayoub E, et al
    Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.
    Blood. 2024;143:1139-1156.
    PubMed         Abstract available


    Br J Cancer

  9. HEYMER EJ, Hawkins MM, Winter DL, Teepen JC, et al
    Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study.
    Br J Cancer. 2024 Jan 19. doi: 10.1038/s41416-024-02577.
    PubMed         Abstract available


    Br J Haematol

  10. LARIBI K, Poulain S, Willems L, Merabet F, et al
    Long-term results of Waldenstrom macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
    Br J Haematol. 2024 Mar 19. doi: 10.1111/bjh.19409.
    PubMed         Abstract available

  11. EADIE LN, Rehn JA, Schutz CE, Heatley SL, et al
    Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling.
    Br J Haematol. 2023;203:282-287.
    PubMed         Abstract available


    Cancer

  12. PALANDRI F, Palumbo GA, Benevolo G, Iurlo A, et al
    Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
    Cancer. 2023 Dec 28. doi: 10.1002/cncr.35156.
    PubMed         Abstract available


    Eur J Haematol

  13. PETIT C, Saillard C, Mohty B, Hicheri Y, et al
    Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
    Eur J Haematol. 2024;112:530-537.
    PubMed         Abstract available

  14. MORI T, Osumi T, Kada A, Ohki K, et al
    Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.
    Eur J Haematol. 2023 Dec 19. doi: 10.1111/ejh.14148.
    PubMed         Abstract available

  15. DELANOTE V, Callens R, Vogelaers D, Deeren D, et al
    Screening for multidrug-resistant organisms in high-risk hospitalized patients with hematologic diseases.
    Eur J Haematol. 2024;112:627-632.
    PubMed         Abstract available

  16. GRONLUND JK, Veigaard C, Juhl-Christensen C, Skou AS, et al
    Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning.
    Eur J Haematol. 2024;112:601-610.
    PubMed         Abstract available

  17. POONSOMBUDLERT K, Mott S, Miller B, Dhakal P, et al
    Transplant versus no transplant in myelodysplastic syndrome and acute myeloid leukemia with TP53 mutation; a referral center experience.
    Eur J Haematol. 2024 Mar 21. doi: 10.1111/ejh.14199.
    PubMed         Abstract available


    Exp Hematol

  18. LIU Q, Zhai Y, Hui Y, Chen J, et al
    Identification of Red blood cell distribution width as a prognostic factor in acute myeloid leukemia.
    Exp Hematol. 2024 Mar 18:104206. doi: 10.1016/j.exphem.2024.104206.
    PubMed         Abstract available


    Int J Hematol

  19. IOANNIDOU M, Avgeros C, Georgiou E, Papadimitriou-Tsantarliotou A, et al
    Effect of apolipoprotein E (APOE) gene polymorphisms on the lipid profile of children being treated for acute lymphoblastic leukemia.
    Int J Hematol. 2024 Mar 20. doi: 10.1007/s12185-024-03748.
    PubMed         Abstract available

  20. TAKIZAWA J, Suzuki R, Izutsu K, Kiguchi T, et al
    Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study.
    Int J Hematol. 2024 Mar 16. doi: 10.1007/s12185-024-03741.
    PubMed         Abstract available

  21. KAWAKAMI Y, Imamura M, Imai C
    Isolated salivary gland extramedullary relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia during blinatumomab treatment.
    Int J Hematol. 2024 Mar 16. doi: 10.1007/s12185-024-03756.
    PubMed        


    J Clin Oncol

  22. BERMAN E, Shah NP, Deninger M, Altman JK, et al
    CML and the WHO: Why?
    J Clin Oncol. 2024;42:984-986.
    PubMed        


    Leuk Lymphoma

  23. ABDALLAH AM, Hafez H, Madney Y, Ahmed S, et al
    Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2024 Mar 21:1-4. doi: 10.1080/10428194.2024.2331625.
    PubMed        

  24. LACZKO D, Poveda-Rogers C, Matthews AH, Snaith O, et al
    RAD21 mutations in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Mar 20:1-7. doi: 10.1080/10428194.2024.2328233.
    PubMed         Abstract available


    Leuk Res

  25. GARCIA-MANERO G, Kazmierczak M, Wierzbowska A, Fong CY, et al
    Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
    Leuk Res. 2024 Mar 12:107480. doi: 10.1016/j.leukres.2024.107480.
    PubMed         Abstract available

  26. WAN CL, Huang YH, Huang SM, Xu YL, et al
    Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study.
    Leuk Res. 2024;139:107483.
    PubMed         Abstract available


    Oncogene

  27. GUO T, Wang Y, Sun X, Hou S, et al
    Loss of RNA-binding protein CELF2 promotes acute leukemia development via FAT10-mTORC1.
    Oncogene. 2024 Mar 21. doi: 10.1038/s41388-024-03006.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  28. SHICHIJO T, Yasunaga JI, Sato K, Nosaka K, et al
    Vulnerability to APOBEC3G linked to the pathogenicity of deltaretroviruses.
    Proc Natl Acad Sci U S A. 2024;121:e2309925121.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.